← back to search

Fereshteh Izadi

Swansea University · GB
Area of research
Surgery · Molecular Biology
Research interest
Research focused on Cancer research and Chemotherapy, with related work in KRAS, CDKN2A, Phosphodiesterase. Notable publications include 'Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts', 'Adipocyte derived exosomes promote cell invasion and challenge paclitaxel efficacy in ovarian cancer', and 'Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma'.
h-index
—
citations
59
works
9
NIH funding
—
primary concept
—
email
✉ Find email ↗

Recent publications

Adipocyte derived exosomes promote cell invasion and challenge paclitaxel efficacy in ovarian cancer
Cell Communication and Signaling 2024cited by 21position: middledoi
Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts
Cell Reports Medicine 2022cited by 24position: middledoi
O086 Genomic analysis of response to neoadjuvant chemotherapy in oesophageal adenocarcinoma
British journal of surgery 2022cited by 0position: middledoi
342. GENOMIC ANALYSIS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN OESOPHAGEAL ADENOCARCINOMA
Diseases of the Esophagus 2022cited by 0position: middledoi
Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
Cancers 2021cited by 10position: firstdoi
Modulation of the Tumor Promoting Functions of Cancer Associated Fibroblasts by Phosphodiesterase Type 5 Inhibition Increases the Efficacy of Chemotherapy in Human Preclinical Models of Esophageal Adenocarcinoma
SSRN Electronic Journal 2021cited by 0position: middledoi
Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma
ePrints Soton (University of Southampton) 2021cited by 0position: middledoi
Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma
Zenodo (CERN European Organization for Nuclear Research) 2021cited by 0position: middledoi
474 GENOMIC ANALYSIS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN ESOPHAGEAL ADENOCARCINOMA
Diseases of the Esophagus 2020cited by 4position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Robert Walker · University of Southampton8 papers (2020–2022)Tim Underwood · NIHR Southampton Respiratory Biomedical Research Unit7 papers (2020–2022)Benjamin P. Sharpe · University of Southampton7 papers (2021–2022)Stella P. Breininger · University of Southampton7 papers (2021–2022)Matthew Rose‐Zerilli · University of Southampton6 papers (2021–2022)Zoë S. Walters · University of Southampton5 papers (2021–2022)Jane Whitney Gibson · University of Central Florida5 papers (2020–2022)Philip A. Clarke · Indiana University School of Medicine4 papers (2021–2022)Maria Secrier · University College London4 papers (2020–2022)Annette Hayden · University of Southampton4 papers (2021–2022)Simon L. Parsons · Galapagos (Belgium)4 papers (2021–2022)Andrew Cowie · University of Southampton4 papers (2021–2022)Anna M. Grabowska · University of Nottingham4 papers (2021–2022)J. Saunders · University of Nottingham4 papers (2021–2022)Spiros D. Garbis · Broadata Communications (United States)4 papers (2021–2022)Rebecca C. Fitzgerald · Cancer Research UK4 papers (2020–2022)Antigoni Manousopoulou · University of Southampton4 papers (2021–2022)Pamela Collier · University of Leicester4 papers (2021–2022)Jack Harrington · University of Southampton4 papers (2021–2022)— · 4 papers (2021–2022)